Cancer Therapy
Liposomal IUdR is an effective radiosensitizer with low toxicity
Published in Medical Devices and Surgical Technology Week, October 17th, 2004
IUdR is "an effective radiosensitizer but its clinical development has been limited by toxicity," oncologists in England explained. "Prolonged intravenous infusions of IUdR are necessary for optimal tumor uptake but cause dose-limiting myelosuppression."
"The lack of selective tumor uptake can lead to radiosensitization of adjacent normal tissues and enhanced local radiation toxicity," stated K.J. Harrington and colleagues at the Institute of Cancer Research in London. "Liposomal IUdR delivery offers selective targeting of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week
More Articles from Medical Devices and Surgical Technology Week
- Drug Delivery
Novel method devised for assessment of drug solubility in polymeric matrices - Knee Replacement
CT navigation associated with improved UKR outcome - Lymphoma Therapy
Novel assays facilitate rituximab monitoring - Medical Devices
Focused ultrasound can induce apoptosis signals in lymphoblasts - Abdominal Aortic Aneurysm
Changes in abdominal aortic aneurysm morphology occur after endovascular repair - Alzheimer Disease
License obtained for brain monitoring technology - More from this issue of Medical Devices and Surgical Technology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
